Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Recurrent Glioblastoma Multiforme
NCT00423735Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2007
- Primary completion
- Mar 2011
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 3
01
Overview
A Phase 2 trial of dasatinib in glioblastoma (GBM), Gliosarcoma (GS), sponsored by National Cancer Institute. Started Jan 2007; status: completed.
02
Drugs
dasatinib
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT00423735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00423735.